临床试验

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

NCT：NCT06246968 · RECRUITING

NCT编号NCT06246968

状态RECRUITING

开始日期2024-01-29

完成时间2027-01-29

SponsorMemorial Sloan Kettering Cancer Center (OTHER)

First posted2024-02-07

Last updated2026-09-14

简要摘要

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。